ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00545532
Recruitment Status : Completed
First Posted : October 17, 2007
Results First Posted : July 12, 2018
Last Update Posted : July 12, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the development of resistant influenza virus. Eligible immunocompromised participants with laboratory-confirmed influenza will be randomized to receive either conventional dose (30 milligrams [mg] to 75 mg twice daily orally [po], depending on age and weight) or double dose (60 mg-150 mg twice daily po depending on age and weight) olseltamivir for 10 days. Nasal and throat swabs will be taken, and safety evaluations made, at intervals during the study. The anticipated time on study medication is 10 days and the anticipated time on study is 40 days.

Condition or disease Intervention/treatment Phase
Influenza, Human Drug: oseltamivir Other: placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 228 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Actual Study Start Date : February 4, 2008
Actual Primary Completion Date : May 2, 2017
Actual Study Completion Date : May 2, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
Drug Information available for: Oseltamivir

Arm Intervention/treatment
Experimental: Conventional dose
Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
Drug: oseltamivir
Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
Other Name: Tamiflu

Other: placebo
Placebo matched to oseltamivir po twice daily for 10 days

Experimental: Double dose
Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
Drug: oseltamivir
Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
Other Name: Tamiflu

Other: placebo
Placebo matched to oseltamivir po twice daily for 10 days




Primary Outcome Measures :
  1. Percentage of Participants With Adverse Events [ Time Frame: Baseline up to Day 40 ]
    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

  2. Percentage of Participants Who Developed Viral Resistance to Oseltamivir [ Time Frame: Baseline up to Day 40 ]
    Resistance was defined as the presence of oseltamivir resistance mutations in viruses isolated from nasopharyngeal swab samples, identified by sequencing of the neuraminidase (NA) and hemagglutinin (HA) genes (genotypic resistance) and/or determination of the oseltamivir concentration at which the response is reduced by half (IC50) in an NA inhibition assay (phenotypic resistance). Reported are post-baseline phenotypic and genotypic resistance in adults >/= 18 years and children and adolescents <18 years in the modified Intent-to-Treat infected (mITTi) population.

  3. Percentage of Participants With Tissue Rejection or Graft Versus Host Disease (GVHD) [ Time Frame: Baseline up to Day 40 ]
    The percentage of transplant patients in the safety population who experienced tissue rejection and/or GvHD is reported.


Secondary Outcome Measures :
  1. Time to Resolution (TTR) of All Clinical Influenza Symptoms [ Time Frame: Baseline up to Day 40 ]
    TTR of all clinical influenza symptoms was defined as the time from treatment initiation to the start of the 24-hour period in which all 7 influenza symptoms had scores </= 1 (mild) and remained </=1 for at least 21.5 hours. . Reported are TTRs in adults >/= 18 years, adults and adolescents >/= 13 years and children <13 years in the mITTi population.

  2. Total Symptom Score Area Under the Efficacy Curve (AUE) [ Time Frame: Baseline up to Day 40 ]
    The overall extent and severity of illness was quantified by the AUE of the total symptom scores over the duration of illness, i.e., from the start of treatment to the time symptoms first alleviated. Total symptom scores were calculated from the sum of seven individual symptom scores with each individual symptom scored from 0 (healthy) to 3 (worst sickness) and a maximum total symptom score of 21. The AUE of these average scores was then calculated for each participant using the trapezoidal rule (the trapezoidal rule calculates the area under any curve by adding up all trapezoids under such a curve). A larger area indicates more severe disease. In this study participants were treated for 10 days. If a participant had scored 21 on every visit then AUE would have been 21 score x 10 days x 24 hours/day =5040 score x hours units, which is the highest possible score. The lowest possible score is 0. Reported are results for adults >/= 18 years in the mITTi population.

  3. Time to Resolution of Fever [ Time Frame: Baseline up to Day 40 ]
    Fever was defined as temperature >/= 37.8 degrees Celsius at any time point during the study. TTR of fever was determined in Adults >/= 18 years, Adults and adolescents >/= 13 years and Children < 13 years of the mITTi population.

  4. Change From Baseline in Viral Load Assessed by Culture [ Time Frame: Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40. ]
    Nasopharyngeal swab samples were cultured in Madin-Darby Canine Kidney cells. Culture supernatants were harvested after 2 weeks, or after a full-blown cytopathic effect was observed. Presence of infectious viruses in the cell culture supernatants (viral titer), expressed as log10 50% Tissue Culture Infectious Dose/milliliter (TCID50/mL), was determined by hemagglutination assay using turkey erythrocytes for H1 and B viruses or by detection of the virus nucleoprotein (NP) using ELISA for H3 viruses. A value of < 0.5 log10 TCID50/mL was interpreted as negative. Data are reported for adults >/= 18 years and adolescents and children < 18 years.

  5. Percentage of Participants With Viral Shedding Assessed by Culture Over Time [ Time Frame: Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40. ]
    Viral shedding was determined through measurement of the viral titer after viral culture in Madin-Darby Canine Kidney cells by hemagglutination assay (for Flu A/H1N1 and Flu B) and NP-ELISA (for Flu A/H3N2) and expressed in log10 TCID50/mL. Reported is the percentage of participants with viral shedding over time in adults >/= 18 years and adolescents and children < 18 years.

  6. Time to Cessation of Viral Shedding by Cell Culture [ Time Frame: Baseline up to Day 40 ]
    Viral shedding was determined through measurement of the viral titer after viral culture in Madin-Darby Canine Kidney cells by hemagglutination assay (for Flu A/H1N1 and Flu B) and NP-ELISA (for Flu A/H3N2) and expressed in log10 TCID50/mL. Reported is the time to cessation of viral shedding over time in adults >/= 18 years and adolescents and children < 18 years.

  7. Change From Baseline in Viral Load Assessed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) [ Time Frame: Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40. ]
    Nasopharyngeal swab samples were tested for influenza A and B RNA using semi-quantitative RT-PCR specific for influenza A and B matrix gene, respectively, after viral RNA isolation. Cycle threshold (Ct) value was determined for each sample. Conversion of Ct values into viral load, expressed as log10 virus particles/mL (vp/mL), was obtained using external standard curves ran in parallel in all RT-PCR experiments. A value of < 2.6 log10 vp/mL for Flu A strains and < 3.0 log10 vp/mL for Flu B strains was interpreted as a negative result. Data are reported for adults >/= 18 years and adolescents and children < 18 years.

  8. Percentage of Participants With Viral Shedding Assessed by RT-PCR Over Time [ Time Frame: Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40. ]
    Viral shedding was determined by direct viral load measurement from nasopharyngeal swabs by RT-PCR assay and expressed in log10 vp/mL. Reported is the percentage of subjects with viral shedding over time in adults >/= 18 years and adolescents and children < 18 years.

  9. Time to Cessation of Viral Shedding by RT-PCR [ Time Frame: Baseline up to Day 40 ]
    Viral shedding was determined by direct viral load measurement from nasopharyngeal swabs by RT-PCR assay and expressed in log10 vp/mL. Reported is the time to cessation of viral shedding over time in adults >/= 18 years and adolescents and children < 18 years.

  10. Percentage of Participants With Persistent Viral Shedding [ Time Frame: Baseline to Day 11 (EOT) ]
    Persistent shedding was defined as a viral load reduction <1 log10 vp/mL at end of treatment compared with baseline. Reported is the percentage of participants with persistent viral shedding at end of treatment in adults >/= 18 years and adolescents and children < 18 years.

  11. Percentage of Participants Who Developed Secondary Illness [ Time Frame: Baseline up to Day 40 ]
    Secondary illness included bronchitis, pneumonia, acute sinusitis, sinusitis, lower respiratory infection or otitis media. Reported is the percentage of participants with at least one event in adults >/= 18 years and adolescents and children < 18 years.

  12. Percentage of Participants Who Initiated Antibiotic Treatment [ Time Frame: Baseline up to Day 40 ]
    Secondary illness included bronchitis, pneumonia, acute sinusitis, sinusitis, lower respiratory infection or otitis media. Reported is the percentage of participants with secondary illness, who initiated antibiotic treatment, in adults >/= 18 years and adolescents and children < 18 years.

  13. Percentage of Participants Hospitalized [ Time Frame: Baseline up to Day 40 ]
    Reported is the percentage of participants, who required hospitalization at any time between treatment initiation and the end of the study period, in adults >/= 18 years and adolescents and children < 18 years.

  14. Duration of Hospitalization [ Time Frame: Baseline up to Day 40 ]
    Reported is the duration of hospitalization at any time between treatment initiation and the end of the study period, in adults >/= 18 years and adolescents and children < 18 years.

  15. Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Oseltamivir in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir Cmax data for adults >/= 18 years.

  16. Pharmacokinetics: Trough Plasma Concentration (Ctrough) of Oseltamivir in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir Ctrough data for adults >/= 18 years.

  17. Pharmacokinetics : Area Under the Concentration-Time Curve From 0 to 12 Hours (AUC0-12) at Steady State of Oseltamivir in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose ]
    AUC0-12 was reported at steady state as nanograms per hour per milliliter. (ng*hr/mL). Reported here are oseltamivir AUC0-12 data for adults >/= 18 years.

  18. Pharmacokinetics: Time to Maximum Concentration (Tmax) of Oseltamivir in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir tmax data for adults >/= 18 years.

  19. Pharmacokinetics: Elimination Constant (ke) of Oseltamivir in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir ke data for adults >/= 18 years.

  20. Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir CL/F data for adults >/= 18 years.

  21. Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir Vc/F data for adults >/= 18 years.

  22. Pharmacokinetics: Cmax of Oseltamivir Carboxylate in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate Cmax data for adults >/= 18 years.

  23. Pharmacokinetics: Ctrough of Oseltamivir Carboxylate in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate Ctrough data for adults >/= 18 years.

  24. Pharmacokinetics : AUC0-12 at Steady State of Oseltamivir Carboxylate in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate AUC0-12 data for adults >/= 18 years.

  25. Pharmacokinetics: Tmax of Oseltamivir Carboxylate in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate tmax data for adults >/= 18 years.

  26. Pharmacokinetics: Elimination Constant (ke) of Oseltamivir Carboxylate in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oxeltamivir carboxylate ke data for adults >/= 18 years.

  27. Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir Carboxylate in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate CL/F data for adults >/= 18 years.

  28. Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir Carboxylate in Adults [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate Vc/F data for adults >/= 18 years.

  29. Pharmacokinetics: Cmax of Oseltamivir in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir Cmax data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  30. Pharmacokinetics: Ctrough of Oseltamivir in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir Ctrough data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  31. Pharmacokinetics: AUC0-12 at Steady State of Oseltamivir in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose ]
    AUC0-12 will be reported at steady state as ng*hr/mL. Reported here are oseltamivir AUC0-12 data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  32. Pharmacokinetics: Tmax of Oseltamivir in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  33. Pharmacokinetics: Cmax of Oseltamivir Carboxylate in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate Cmax data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  34. Pharmacokinetics: Ctrough of Oseltamivir Carboxylate in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate Ctrough data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  35. Pharmacokinetics: AUC0-12 at Steady State of Oseltamivir Carboxylate in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose ]
    AUC0-12 will be reported at steady state as ng*hr/mL. Reported here are oseltamivir carboxylate AUC0-12 data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  36. Pharmacokinetics: Tmax of Oseltamivir Carboxylate in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate tmax data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  37. Pharmacokinetics: Elimination Constant (ke) of Oseltamivir in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir ke data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  38. Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir CL/F data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  39. Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir Vc/F data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  40. Pharmacokinetics: Elimination Constant (ke) of Oseltamivir Carboxylate in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate ke data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  41. Pharmacokinetics: Apparent Clearance (CL/F), of Oseltamivir Carboxylate in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate CL/F data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.

  42. Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir Carboxylate in Adolescents and Children [ Time Frame: Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose ]
    Reported here are oseltamivir carboxylate Vc/F data for adolescents and children < 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Rapid diagnostic test, PCR, or viral culture positive for influenza in the 96 hours prior to first dose
  • Immunocompromised participants with primary or secondary immunodeficiency
  • Symptoms suggestive of influenza-like illness
  • Use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding

Exclusion Criteria:

  • Influenza vaccination with live attenuated vaccine in the 2 weeks prior to randomization
  • Antiviral treatment for influenza in 2 weeks prior to randomization
  • Severe hepatic impairment
  • Any current renal replacement therapy
  • Any gastrointestinal disorders which may interfere with the absorption of oseltamivir
  • Participation in a study with an investigational drug from 4 weeks prior to study start until study end

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00545532


  Show 208 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  Study Documents (Full-Text)

Documents provided by Hoffmann-La Roche:
Study Protocol  [PDF] June 18, 2014
Statistical Analysis Plan  [PDF] August 4, 2017


Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00545532     History of Changes
Other Study ID Numbers: NV20234
2006-002468-24 ( EudraCT Number )
First Posted: October 17, 2007    Key Record Dates
Results First Posted: July 12, 2018
Last Update Posted: July 12, 2018
Last Verified: June 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Oseltamivir
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action